Sample size determination in clinical trials with multiple co-primary binary endpoints

被引:45
|
作者
Sozu, Takashi [1 ,2 ]
Sugimoto, Tomoyuki [2 ]
Hamasaki, Toshimitsu [1 ,2 ]
机构
[1] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate Bernoulli; association measures; continuity correction; arcsine transformation; Fisher's exact method; EFFICACY; DESIGN; ISSUES; POWER;
D O I
10.1002/sim.3972
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
下载
收藏
页码:2169 / 2179
页数:11
相关论文
共 50 条
  • [21] Blinded sample size recalculation in clinical trials with binary composite endpoints
    Sander, Anja
    Rauch, Geraldine
    Kieser, Meinhard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (04) : 705 - 715
  • [22] Changes are still needed on multiple co-primary endpoints
    Chuang-Stein, Christy
    Li, Jianjun
    STATISTICS IN MEDICINE, 2017, 36 (28) : 4427 - 4436
  • [23] Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction
    Asakura, Koko
    Evans, Scott R.
    Hamasaki, Toshimitsu
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (02): : 164 - 175
  • [24] Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Evans, Scott R.
    BIOMETRICAL JOURNAL, 2017, 59 (04) : 703 - 731
  • [25] BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Binary, Co-primary and Other Complex Endpoints
    Yuan, Ying
    Zhou, Heng
    Lee, Jack
    TRIALS, 2019, 20
  • [26] BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints
    Chi, Xiaohan
    Yu, Zhangsheng
    Lin, Ruitao
    STATISTICS IN MEDICINE, 2022, 41 (26) : 5319 - 5334
  • [27] Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease
    Chung Sang Tse
    Vipul Jairath
    Brian G. Feagan
    William J. Sandborn
    Current Treatment Options in Gastroenterology, 2021, 19 (4) : 608 - 627
  • [28] Fallback tests for co-primary endpoints
    Ristl, Robin
    Frommlet, Florian
    Koch, Armin
    Posch, Martin
    STATISTICS IN MEDICINE, 2016, 35 (16) : 2669 - 2686
  • [29] A multiple testing framework for diagnostic accuracy studies with co-primary endpoints
    Westphal, Max
    Zapf, Antonia
    Brannath, Werner
    STATISTICS IN MEDICINE, 2022, 41 (05) : 891 - 909
  • [30] Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes
    Hamasaki, Toshimitsu
    Asakura, Koko
    Evans, Scott R.
    Sugimoto, Tomoyuki
    Sozu, Takashi
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (01): : 36 - 54